Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.

Biotechnology

UFOVAX

UFOVAX's headquarters in Wilmington, DE, United States

Ji Li

Jiang Zhu

Robin Shattock

Drew Weissman

Ian Wilson

The UFOVAX leadership team has experience in the board of directors at Molecular Targeting Technology, Inc., as the president and CEO at Uvax Bio, and as a director at Wilmington PharmaTech Company LLC. They also have a managing director for the Feixiang Group's M&A, technology development, and pharmaceutical division. The team is educated from Princeton University in organic chemistry.

UFOVAX

Org chart

Board & advisors

Teams

Leadership Team

Offices

UFOVAX

Org chart

Board & advisors

Teams

Leadership Team

Offices

Related companies